Targeting specific mutations in glioblastoma to improve treatment outcomes
Small molecule inhibitors with a therapeutic window for EGFR signaling variants in glioblastoma
This study is working on new medications that can specifically target and block the harmful effects of certain mutations in a gene called EGFR, which is involved in a tough type of brain cancer called glioblastoma, aiming to provide a more personalized and effective treatment for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10911191 on NIH RePORTER |
What this research studies
This research focuses on developing small molecule inhibitors that specifically target mutated forms of the epidermal growth factor receptor (EGFR) in glioblastoma, a type of aggressive brain cancer. The approach aims to create drugs that can effectively block the harmful signaling caused by these mutations while minimizing side effects on normal EGFR signaling. By utilizing an allosteric mechanism, the goal is to achieve a therapeutic window that allows for effective treatment of patients with EGFR-driven glioblastoma. Patients may benefit from a more tailored treatment option that addresses the unique genetic characteristics of their tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who have mutations or amplifications in the EGFR gene.
Not a fit: Patients with glioblastoma who do not have EGFR mutations or amplifications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma patients with specific EGFR mutations, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research in other cancers, such as non-small cell lung cancer, has shown that targeting specific mutations in EGFR can lead to significant treatment advancements, suggesting potential success for this approach in glioblastoma.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Eck, Michael J — Brigham and Women's Hospital
- Study coordinator: Eck, Michael J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.